🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)

RecruitingNAAges 18 Years - anyAllUniversity of Manitoba
NCT04923984 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: \- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic. Exclusion Criteria: * If informed consent cannot be obtained from the patient or their substitute decision maker. * Known allergy to liquid embolic agent
💊

What it tests

  • Embolization of the middle meningeal artery
📍

Where

1 site
Health Sciences centre
Winnipeg MB, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy